FrancophonIA/ELRC3.0 huggingface dataset:
English: Tamoxifen, other anti-oestrogens or oestrogen-containing therapies may diminish the pharmacological action of letrozole.
Slovenian: Tamoksifen, drugi antiestrogeni ali zdravila, ki vsebujejo estrogene, lahko zmanjšajo farmakološko delovanje letrozola.
English: The primary endpoint was disease-free survival (DFS); secondary efficacy endpoints were time to distant metastasis (TDM), distant disease-free survival (DDFS), overall survival (OS), systemic disease-free survival (SDFS), invasive contralateral breast cancer and time to breast cancer recurrence.
Slovenian: Primarni cilj opazovanja je bilo preživetje brez ponovitve bolezni (disease free survival -DFS), sekundarni cilji opazovanja pa so bili čas do pojava oddaljenih metastaz (time to distant metastasisTDM), preživetje brez oddaljene ponovitve bolezni (distant disease free survival -DDFS), celokupno preživetje, preživetje brez generalizacije bolezni (systemic disease-free survival - SDFS), invazivni rak kontralateralne dojke in čas do ponovitve raka dojke.
English: The ACTH stimulation test performed after 6 and 12 weeks of treatment with daily doses of 0.1 mg, 0.25 mg, 0.5 mg, 1 mg, 2.5 mg, and 5 mg did not indicate any attenuation of aldosterone or cortisol production.
Slovenian: Rezultati testa stimulacije z ACTH, ki so ga izvajali po 6 in 12 tednih zdravljenja z dnevnimi odmerki 0,1 mg, 0,25 mg, 0,5 mg, 1 mg, 2,5 mg ali 5 mg, niso pokazali, da bi bilo nastajanja aldosterona ali kortizola kakorkoli zmanjšano.
English: Efficacy results at a median follow-up of 26 and 60 months Data in Table 4 reflect the results of the Primary Core Analysis (PCA) based on data from the monotherapy arms (A and B) and from the two switching arms (C and D) at a median treatment duration of 24 months and a median follow-up of 26 months and at a median treatment duration of 32 months and a median follow-up of 60 months.
Slovenian: Rezultati glede učinkovitosti po medianem trajanju spremljanja 26 in 60 mesecev Podatki v preglednici 4 kažejo rezultate primarne osrednje analize podatkov iz skupin bolnic, ki so prejemale monoterapijo (skupin A in B), in skupin bolnic, ki so prejemale eno zdravilo za drugim (skupin C in D) po medianem trajanju zdravljenja 24 mesecev in medianem trajanju spremljanja bolnic 26 mesecev oziroma po medianem trajanju zdravljenja 32 mesecev in medianem trajanju spremljanja bolnic 60 mesecev.
English: Based on human experience in which there have been isolated cases of birth defects (labial fusion, ambiguous genitalia), {Invented Name} may cause congenital malformations when administered during pregnancy.
Slovenian: Na podlagi izkušenj pri ljudeh, ki vključujejo tudi posamezne primere prirojenih okvar (zraščene male sramne ustnice, neopredeljene genitalije glede spola), lahko zdravilo {Izmišljeno ime} povzroča kongenitalne malformacije, če ga jemljejo nosečnice.
English: Warnings and precautions Talk to your doctor or pharmacist before taking {Invented Name} if you have a severe kidney disease, if you have a severe liver disease, if you have a history of osteoporosis or bone fractures (see also “Follow-up during {Invented Name} treatment” in section 3).
Slovenian: Pred začetkom jemanja zdravila {Izmišljeno ime} se posvetujte s svojim zdravnikom ali farmacevtom: - če imate hudo bolezen ledvic, - če imate hudo bolezen jeter, - če ste imeli že prej osteoporozo ali zlome kosti (glejte tudi "Pregledi v času zdravljenja z zdravilom {Izmišljeno ime}" v poglavju 3).
English: Insufficient data are available for patients with severe hepatic impairment.
Slovenian: Za bolnice s hudo okvaro jeter ni na voljo dovolj podatkov.
English: Over 60% of eligible patients (disease-free at unblinding) opted to switch to {Invented Name}.
Slovenian: Več kot 60 % bolnic, ki so bile primerne za zamenjavo zdravila (če v času razkritja niso imele ponovitve bolezni), se je odločilo za prehod na zdravilo {Izmišljeno ime}.
English: Renal impairment {Invented Name} has not been investigated in a sufficient number of patients with a creatinine clearance lower than 10 ml/min.
Slovenian: Zdravila {Izmišljeno ime} niso raziskali pri zadostnem številu bolnic z očistkom kreatinina manj kot 10 ml/min.
English: A total of 262 patients were assigned either letrozole for 5 years or tamoxifen for 2 years followed by letrozole for 3 years.
Slovenian: Skupno so 262 bolnic randomizirali tako, da so bodisi 5 let prejemale letrozol ali pa 2 leti tamoksifen in nato 3 leta letrozol.
English: Within 2 weeks after administration of 2.5 mg 14C
Slovenian: V 2 tednih po odmerjanju 2,5 mg letrozola, označenega s 14C,
English: Primary Core Analysis Median follow-up 26 months
Slovenian: Primarna osnovna analiza mediano trajanje spremljanja 26 mesecev mediano trajanje spremljanja 60 mesecev
English: The following adverse drug reactions, listed in Table 1, were reported from clinical studies and from postmarketing experience with {Invented Name}:
Slovenian: O neželenih učinkih zdravila, ki so našteti v preglednici 1, so poročali v kliničnih študijah in na podlagi izkušenj z zdravilom {Izmišljeno ime} po njegovem prihodu na trg.
English: • Neo-adjuvant treatment of postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery not indicated.
Slovenian: • Neoadjuvantno zdravljenje žensk v pomenopavzi, ki imajo HER-2 negativen rak dojke, pozitiven na hormonske receptorje, in pri katerih zdravljenje s kemoterapijo ni primerno, takojšen kirurški poseg pa ni indiciran.
English: Coadministration of letrozole with tamoxifen, other anti-oestrogens or oestrogens should be avoided.
Slovenian: Sočasni uporabi letrozola s tamoksifenom, z drugimi antiestrogeni ali z estrogeni se je treba izogibati.
English: In patients with advanced or metastatic breast cancer, treatment with {Invented Name} should continue until tumour progression is evident.
Slovenian: Pri bolnicah z napredovalim ali razsejanim rakom dojke je zdravljenje z zdravilom{Izmišljeno ime} smiselno nadaljevati, dokler ne gre za očitno napredovanje tumorja.
English: Formation of minor unidentified metabolites and direct renal and faecal excretion play only a minor role in the overall elimination of letrozole.
Slovenian: Nastajanje manj pomembnih neidentificiranih presnovkov in neposredno izločanje skozi ledvice in z blatom sta pri celokupnem odstranjevanju letrozola iz telesa manj pomembna.
English: In the MA-17 lipid substudy there were no significant differences between letrozole and placebo in total cholesterol or in any lipid fraction.
Slovenian: V podštudiji lipidov v okviru študije MA-17 ni prišlo do nobene značilne razlike med letrozolom in placebom kar zadeva koncentracijo celotnega holesterola ali koncentracije lipidnih frakcij.
English: Rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (signs of skin disorder).
Slovenian: - izpuščaj, rdeča koža, pojavljanje mehurčkov na ustnicah, očeh ali v ustih, luščenje kože, zvišana telesna temperatura (znaki kožnih bolezni).
English: These side effects may affect between 1 to 10 in every 100 patients.
Slovenian: Lahko se pojavijo pri 1 do 10 na vsakih 100 bolnikov.
English: Continue taking {Invented Name} every day for as long as your doctor tells you.
Slovenian: Kako dolgo je treba jemati zdravilo {Izmišljeno ime} Zdravilo {Izmišljeno ime} jemljite vsak dan in sicer tako dolgo, kot vam je naročil zdravnik.
English: In a similar study involving subjects with varying degrees of hepatic function, the mean AUC values of the volunteers with moderate hepatic impairment (Child-Pugh B) was 37% higher than in normal subjects, but still within the range seen in subjects without impaired function.
Slovenian: V podobni študiji z osebami z različnimi stopnjami delovanja jeter so bile pri prostovoljkah z zmerno okvaro jeter (Child-Pugh razreda B) povprečne vrednosti AUC za 37 % večje kot pri zdravih osebah, a še vedno v okviru meja, ki veljajo za osebe brez okvarjenega delovanja jeter.
English: If you have any questions about how long to keep taking {Invented Name}, talk to your doctor.
Slovenian: Če bi radi izvedeli, kako dolgo boste jemali zdravilo {Izmišljeno ime}, se obrnite na svojega zdravnika.
English: Approximately 50% of patients crossed over to the opposite treatment arm and crossover was virtually completed by 36 months.
Slovenian: Približno 50 % bolnic je prešlo na uporabo drugega zdravila, prehod iz ene zdravljene skupine v drugo pa je bil do konca 36. tedna praktično zaključen.
English: 4 Exploratory analysis, censoring follow-up times at the date of switch (if it occurred) in the placebo arm.
Slovenian: 4 eksploratorna analiza s cenzuriranjem časa spremljanja bolnic iz skupine s placebom na datum zamenjave zdravila (če je do nje prišlo).
English: Adjusted by chemotherapy use (yes/no) 624 (40%) patients selectively crossed to letrozole after tamoxifen arm unblinded in 2005
Slovenian: 1 prilagojeno na uporabo kemoterapije (možnosti da/ne) 2 624 (40%) bolnic iz skupine s tamoksifenom je selektivno prešlo na uporabo letrozola, ko so leta 2005 razkrili slepo zdravljenje
English: Time to progression was significantly longer for letrozole irrespective of dominant site of disease.
Slovenian: V skupini z letrozolom je bil čas do napredovanja bolezni statistično značilno daljši ne glede na dominantno mesto zasevanja.
English: Nervous disorders such as anxiety, nervousness, irritability, drowsiness, memory problems, somnolence, insomnia
Slovenian: - bolezni živcev, kot so tesnoba, nervoznost, razdražljivost, dremavost, težave s spominom,
English: The results for total hip BMD were similar to those for lumbar spine but less pronounced.
Slovenian: Rezultati pri celokupni mineralni gostoti kolka so bili podobni kot pri mineralni gostoti ledvenega dela hrbtenice, le manj izraziti.
English: In vitro, letrozole inhibits the cytochrome P450 isoenzymes 2A6 and, moderately, 2C19, but the clinical relevance is unkown.
Slovenian: Letrozol in vitro zavira izoencima citokroma P450, in sicer izoencim 2A6 in zmerno tudi izoencim 2C19, vendar klinični pomen tega pojava ni znan.
English: The other ingredients are [To be completed nationally] What {Invented Name} looks like and contents of the pack [To be completed nationally]
Slovenian: - Druge sestavine zdravila so [izpolni država članica] Izgled zdravila {Izmišljeno ime} in vsebina pakiranja [izpolni država članica]
English: • Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.
Slovenian: • Podaljšano adjuvantno zdravljenje invazivnega, hormonsko odvisnega raka dojke pri ženskah v pomenopavzi, ki so 5 let prejemale predhodno standardno adjuvantno zdravljenje s tamoksifenom.
English: After daily administration of 2.5 mg steady-state levels are reached within 2 to 6 weeks.
Slovenian: Po odmerjanju 2,5 mg dnevno pride do stanja dinamičnega ravnovesja v 2 do 6 tednih.
English: If any of these conditions apply to you, tell your doctor.
Slovenian: Če karkoli od navedenega velja za vas, povejte svojemu zdravniku.
English: Letrozole is rapidly and extensively distributed to tissues.
Slovenian: Letrozol se hitro in obsežno porazdeli po tkivih.
English: Only women of postmenopausal endocrine status should receive {Invented Name}.
Slovenian: Zdravilo {Izmišljeno ime} smejo prejemati samo ženske s postmenopavznim endokrinim statusom.
English: At 24 months there was a statistically significant difference in the primary end-point; the lumbar spine BMD (L2-L4) showed a median decrease of 4.1% for letrozole compared to a median increase of 0.3% for tamoxifen.
Slovenian: Po 24 mesecih je prišlo do statistično značilne razlike pri primarnem cilju opazovanja: mineralna gostota ledvenega dela hrbtenice (L2-L4) se je mediano zmanjšala za 4,1 % v skupini z letrozolom v primerjavi z medianim povečanjem za 0,3 % v skupini s tamoksifenom.
English: In a study comparing the pharmacokinetics of letrozole after a single oral dose in eight male subjects with liver cirrhosis and severe hepatic impairment (Child-Pugh C) to those in healthy volunteers (N=8), AUC and t½ increased by 95 and 187%, respectively.
Slovenian: V študiji, v kateri so primerjali farmakokinetiko letrozola po enem samem peroralnem odmerku pri osmih osebah moškega spola s cirozo jeter in hudo okvaro jeter (Child-Pugh razreda C) s farmakokinetiko pri zdravih prostovoljkah (N = 8), je bila AUC večja za 95 %, t1/2 pa daljši za 187 %.
English: Somnolence, insomnia, memory impairment, dysaesthesia (including paraesthesia, hypoaesthesia), taste disturbance, cerebrovascular accident
Slovenian: somnolenca, nespečnost, motnje spomina, disestezija (vključno s parestezijami in hipestezijo), motnje okušanja, cerebrovaskularni zaplet
English: The following tables provide information on significant differences in {Invented Name} versus tamoxifen monotherapy and in the {Invented Name}-tamoxifen sequential treatment therapy:
Slovenian: V naslednjih preglednicah so navedeni podatki o pomembnih razlikah pri zdravljenju z zdravilom {Izmišljeno ime} v primerjavi z monoterapijo s tamoksifenom ter s sekvenčnim zdravljenjem z zdravilom { Izmišljeno ime} in tamoksifenom:
English: Consequently, after the the first interim analysis the study was unblinded and continued in an open-label fashion and patients in the placebo arm were allowed to switch to {Invented Name} for up to 5 years.
Slovenian: Kasneje so po prvi vmesni analizi razkrili do tedaj slepo zdravljenje in bolnicam iz skupine s placebom dovolili prehod na uporabo zdravila {Izmišljeno ime} za največ 5 let.
English: {Invented Name} N=4003
Slovenian: {Izmišljeno ime} N=4.003
English: In the extended adjuvant setting, significantly more patients treated with {Invented Name} experienced bone fractures or osteoporosis (bone fractures, 10.4% and osteoporosis, 12.2%) than patients in the placebo arm (5.8% and 6.4%, respectively).
Slovenian: V okviru podaljšanega adjuvantnega zdravljenja je prišlo do zlomov kosti ali do osteoporoze pri bistveno več bolnicah, ki so jemale zdravilo {Izmišljeno ime}, (zlomi kosti pri 10,4 % in osteoporoza pri 12,2 %) v primerjavi z bolnicami iz skupine s placebom (5,8 % oziroma 6,4 %).
English: Table 7 Sequential Treatments Analyses from randomisation (STA-R) of disease-free survival (ITT STA-R population)
Slovenian: Preglednica 7 Analiza sekvenčnega zdravljenja pri bolnicah, ki so bile randomizirane v tovrstne skupine (skupine STA-R): preživetje brez ponovitve bolezni (populacija ITT STA-R)
English: Overall survival was not significantly different between the 2 arms (P=0.2).
Slovenian: Celokupno preživetje se med obema skupinama bolnic ni statistično značilno razlikovalo (P=0,2).
English: {Invented Name} is contraindicated during breast-feeding (see section 4.3).
Slovenian: Zdravilo {Izmišljeno ime} je kontraindicirano med dojenjem (glejte poglavje 4.3).
English: This medicinal product is authorised in the Member States of the EEA under the following names: [See Annex I - To be completed nationally]
Slovenian: Zdravilo je v državah članicah EGP pridobilo dovoljenje za promet z naslednjimi imeni: [glejte Prilogo I - izpolni država članica]
English: There was no significant difference in overall survival: ({Invented Name} 51 deaths; placebo 62; HR 0.82; 95% CI 0.56, 1.19).
Slovenian: Pri celokupnem preživetju ni prišlo do značilne razlike: v skupini z zdravilom {Izmišljeno ime} je umrlo 51 bolnic, v skupini s placebom pa 62; razmerje ogroženosti 0,82; 95-odstotni IZ 0,56, 1,19).
English: In healthy postmenopausal women, single doses of 0.1 mg, 0.5 mg, and 2.5 mg letrozole suppress serum oestrone and oestradiol by 75%, 78% and 78% from baseline, respectively.
Slovenian: Pri zdravih ženskah v pomenopavzi posamezni odmerki 0,1 mg, 0,5 mg in 2,5 mg letrozola znižajo koncentracije estrona in estradiola v serumu za 75 %, 78 % in 78 % od izhodiščne vrednosti.
English: There was no significant difference between treatments in the rate of fractures - 15% in the letrozole arm, 17% in the tamoxifen arm.
Slovenian: Pogostnost zlomov se med obema načinom zdravljenja ni značilno razlikovala - v skupini z letrozolom je bila pogostnost 15 %, v skupini s tamoksifenom pa 17 %.
English: Plasma concentrations at steady state are approximately 7 times higher than concentrations measured after a single dose of 2.5 mg, while they are 1.5 to 2 times higher than the steady-state values predicted from the concentrations measured after a single dose, indicating a slight non-linearity in the pharmacokinetics of letrozole upon daily administration of 2.5 mg.
Slovenian: V stanju dinamičnega ravnovesja je koncentracija v plazmi približno 7-krat višja od koncentracije po enkratnem odmerku 2,5 mg in 1,5- do 2-krat višja od koncentracije, ki bi jo za stanje dinamičnega ravnovesja napovedali glede na koncentracijo, izmerjeno po enkratnem odmerku, kar kaže na blago nelinearnost v farmakokinetiki letrozola pri odmerjanju 2,5 mg dnevno.
English: In addition, co-administration of tamoxifen with letrozole has been shown to substantially decrease plasma concentrations of letrozole.
Slovenian: Poleg tega so dokazali, da sočasna uporaba tamoksifena in letrozola bistveno zniža koncentracijo letrozola v plazmi.
English: In patients whose menopausal status is unclear, luteinising hormone (LH), follicle-stimulating hormone (FSH) and/or oestradiol levels should be measured before initiating treatment with {Invented Name}.
Slovenian: Pri bolnicah z nejasnim menopavznim statusom je treba pred začetkom zdravljenja z zdravilom {Izmišljeno ime} izmeriti koncentracije luteinizirajočega hormona (LH), folikel stimulirajočega hormona (FSH) in/ali estradiola.
English: Letrozole N=2582
Slovenian: letrozol N=2.582
English: Statistically significant differences were observed in favour of letrozole 2.5 mg compared to megestrol acetate in overall objective tumour response rate (24% vs 16%, P=0.04), and in time to treatment failure (P=0.04).
Slovenian: Statistično značilno razliko v prid letrozolu 2,5 mg v primerjavi z megestrol acetatom pa so opažali pri deležu bolnic z objektivnim celokupnim odzivom tumorja (24 % v primerjavi s 16 %, P=0,04) in pri času do prenehanja učinkovitosti zdravljenja (P=0,04).
English: Median follow-up was 73 months.
Slovenian: Mediano trajanje spremljanja bolnic po zaključku študije je bilo 73 mesecev.
English: Urinary tract infection Neoplasms, benign, malignant and unspecified (including cysts and polyps) Uncommon:
Slovenian: okužba sečil Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi) občasni:
English: The only statistically significant difference occurred at 2 years and was in total hip BMD (letrozole median decrease of 3.8% vs placebo median decrease of 2.0%).
Slovenian: Do edine statistično značilne razlike je prišlo po 2 letih, in sicer pri celokupni mineralni gostoti kolka (pri uporabi letrozola je prišlo do medianega zmanjšanja za 3,8 % v primerjavi z medianim zmanjšanjem za 2,0 % pri uporabi placeba).
English: You should only take this medicine under strict medical supervision.
Slovenian: Pregledi v času zdravljenja z zdravilom {Izmišljeno ime} Zdravilo {Izmišljeno ime} smete jemati samo pod skrbnim zdravniškim nadzorom.
English: Hepatitis Skin and subcutaneous tissue disorders Very common:
Slovenian: hepatitis Bolezni kože in podkožja zelo pogosti:
English: • First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.
Slovenian: • Zdravljenje prve izbire pri ženskah v pomenopavzi s hormonsko odvisnim napredovalim rakom dojke.
English: No patient with a normal BMD at baseline became osteoporotic during 2 years of treatment and only 1 patient with osteopenia at baseline (T score of -1.9) developed osteoporosis during the treatment period (assessment by central review).
Slovenian: Pri nobeni bolnici z normalno mineralno gostoto kosti ob izhodišču po 2 letih ni prišlo do osteoporoze, do osteoporoze (po oceni centralnega pregledovalca) v času zdravljenja pa je prišlo samo pri 1 bolnici, ki je imela ob izhodišču osteopenijo (vrednost T -1,9).
English: In the letrozole arm, total cholesterol levels were relatively stable over time, giving a statistically significant difference in favor of tamoxifen at each time point.
Slovenian: V skupini z letrozolom je bila koncentracija celokupnega holesterola sorazmerno stabilna, tako da je bila razlika med obema skupinama bolnic ob vsakem času opazovanja statistično značilna v korist tamoksifena.
English: Insufficient data are available in cases of renal insufficiency with creatinine clearance lower than 10 ml/min (see sections 4.4 and 5.2).
Slovenian: Za primere s poslabšanim delovanjem ledvic, pri kateri je očistek kreatinina manjši od 10 ml/min, ni na voljo dovolj podatkov (glejte poglavji 4.4 in
English: Treatment or prophylaxis for osteoporosis should be initiated as appropriate and carefully monitored.
Slovenian: Po potrebi je treba pri bolnici uvesti zdravljenje osteoporoze ali preventivne ukrepe proti osteoporozi in stanje skrbno spremljati.
English: The analyses presented here ignore the selective crossover.
Slovenian: Prikazni so rezultati analize, v kateri niso upoštevali te selektivne zamenjave zdravil.
English: What you need to know befor you take {Invented Name}
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo {Izmišljeno ime}
English: Thus, {Invented Name} should be administered with caution to patients with severe hepatic impairment and after consideration of the risk/benefit in the individual patient.
Slovenian: Zato je treba zdravilo {Izmišljeno ime} pri bolnicah s hudo okvaro jeter uporabljati previdno in prej pretehtati razmerje med tveganji in koristmi za posamezno bolnico.
English: In the adjuvant and extended adjuvant setting, treatment with {Invented Name} should continue for 5 years or until tumour relapse occurs, whichever is first.
Slovenian: V okviru adjuvantnega in podaljšanega adjuvantnega zdravljenja je z uporabo zdravila {Izmišljeno ime} smiselno nadaljevati 5 let oziroma dokler ne pride do recidiva tumorja, kar od navedenega se zgodi prej.
English: Isolated cases of overdose with {Invented Name} have been reported.
Slovenian: Poročali so o posameznih primerih prevelikega odmerjanja zdravila {Izmišljeno ime}.
English: {Invented Name} treatment in the first-line therapy of advanced breast cancer resulted in a median overall survival of 34 months compared with 30 months for tamoxifen (logrank test P=0.53, not significant).
Slovenian: Pri bolnicah, ki so prejemale zdravilo {Izmišljeno ime} kot zdravilo prvega izbora za zdravljenje napredovalega raka dojke, je mediano celokupno preživetje trajalo 34 mesecev v primerjavi s 30 meseci pri bolnicah, ki so začele zdravljenje s tamoksifenom (vrednost P za test logrank ni značilna, P=0,53).
English: A double blind trial (P024) was conducted in 337 postmenopausal breast cancer patients randomly allocated either {Invented Name} 2.5 mg for 4 months or tamoxifen for 4 months.
Slovenian: Dvojno slepo preskušanje (P024) so izvajali pri 337 bolnicah v pomenopavzi z rakom dojke, ki so jih naključno razporedili bodisi v skupino, v kateri so bolnice 4 mesece prejemale zdravilo {Izmišljeno ime} v odmerku 2,5 mg, ali pa v skupino, v kateri so 4 mesece prejemale tamoksifen.
English: The pharmacological action of letrozole is to reduce oestrogen production by aromatase inhibition.
Slovenian: Letrozol farmakološko deluje tako, da z zaviranjem aromataze zmanjšuje nastajanje estrogenov.
English: Growth of breast cancer is frequently stimulated by oestrogens which are female sex hormones.
Slovenian: Pogosto estrogeni, to so ženski spolni hormoni, spodbujajo rast raka dojke.
English: In the second study, the response rate was not significantly different between letrozole 2.5 mg and aminoglutethimide (P=0.06).
Slovenian: V drugi študiji se delež bolnic z odzivom ni značilno razlikoval med skupino z letrozolom 2,5 mg in skupino z aminoglutetimidom (P=0,06).
English: Events marked * were statistically significantly different in the two treatment arms.
Slovenian: Pri dogodkih, označenih z *, je bila razlika med zdravljenima skupinama statistično značilna.
English: Tamoxifen N=2459
Slovenian: tamoksifen N=2459
English: {Invented Name}>tamoxifen
Slovenian: {Izmišljeno ime}>tamoksifen tamoksifen>{Izmišljeno ime}